Roivant Sciences (ROIV) Price & Analysis

Compare

694 Followers

ROIV Stock Chart & Stats

$20.24

-$0.41(-3.60%)

At close: Jan 08 4:00 PM EST

$20.24

-$0.41(-3.60%)

Day’s Range― - ―

52-Week Range$8.73 - $21.48

Previous CloseN/A

Volume1.46M

Average Volume (3M)7.37M

Market Cap

$14.60B

Enterprise Value$6.46B

Total Cash (Recent Filing)$4.39B

Total Debt (Recent Filing)$98.85M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Feb 16, 2026

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding695,491,640

10 Day Avg. Volume5,144,904

30 Day Avg. Volume7,372,200

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.56

Price to Sales (P/S)251.93

P/FCF Ratio-8.67

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue317.61

Enterprise Value/Gross Profit329.42

Enterprise Value/Ebitda-6.48

Forecast

1Y Price Target

$24.50

Price Target Upside21.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company has a cash balance of $4.4B, which is expected to fund operations to profitability.

Pipeline ProgressRoivant has guided to filing an NDA for brepocitinib in DM, indicating progress in their development pipeline.

Therapeutic AdvancementsRoivant reported positive data in DM that positions the company to have a first-in-class therapy in a disease with high unmet need and few therapeutic options.

Bears Say

Efficacy ConcernsThe primary efficacy of brepocitinib came in modestly below pipeline competitors.

Revenue DeclineRoivant reported total revenue of $1.6M, which is a 65% decrease year-over-year and below estimates.

Safety WarningsRoivant expects brepo to carry class-related label safety warning.

Roivant Sciences News

Roivant Sciences highlights pipeline progress at Investor Day

Roivant is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and...

14h ago

ROIV

Moderna price target raised to $18 from $15 at Leerink

Leerink raised the firm’s price target on Moderna (MRNA) to $18 from $15 and keeps an Underperform rating...

21d ago

MRNA

ROIV

Einhorn’s DME Capital bought PG&E and United Parks in Q3

David Einhorn’s DME Capital Management disclosed in an SEC filing its holdings as of September 30, 2025. The...

27d ago

BHF

Roivant Sciences price target raised to $23 from $20 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $23 from $20...

27d ago

ROIV

Roivant Sciences price target raised to $25 from $21 at Guggenheim

Guggenheim analyst Yastin Suneja raised the firm’s price target on Roivant Sciences (ROIV) to $25 from $21 and...

28d ago

ROIV

Roivant Sciences Highlights Pipeline Progress at Investor Day

An announcement from Roivant Sciences ( ($ROIV) ) is now available. On December 11, 2025, Roivant Sciences hosted...

13h ago

ROIV

Roivant Sciences Reports Q2 2025 Financial Results

Roivant Sciences Ltd. ( ($ROIV) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

ROIV

Roivant Sciences price target raised to $26 from $25 at Citi

Citi analyst Samantha Semenkow raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $25 and...

1M ago

ROIV

Promising Developments and Strong Financial Position Justify Buy Rating for Roivant Sciences

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences, with...

1M ago

ROIV

Roivant Sciences reports Q2 EPS (17c), consensus (30c)

Reports Q2 revenue $1.6M, consensus $6.92M. “This quarter unquestionably represents a moment of transformation for Roivant, with the...

1M ago

ROIV

Roivant Sciences sees cash runway into profitability

Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.4 billion as of September 30,...

1M ago

ROIV

ROIV Upcoming Earnings Report: What to Expect?

Roivant Sciences Ltd. (ROIV) is scheduled to report 2nd quarter earnings on 11/10/2025, before the market opens. Regarding...

1M ago

ROIV

Vor Bio appoints Sokolove as Chief Medical Officer

Vor Bio (VOR) announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Most recently, Dr. Sokolove...

1M ago

VOR

ROIV

Roivant Sciences price target raised to $25 from $16 at Citi

Citi raised the firm’s price target on Roivant Sciences (ROIV) to $25 from $16 and keeps a Buy...

1M ago

ROIV

ROIV FAQ

What was Roivant Sciences’s price range in the past 12 months?

Roivant Sciences lowest stock price was $8.73 and its highest was $21.48 in the past 12 months.

What is Roivant Sciences’s market cap?

Roivant Sciences’s market cap is $14.60B.

When is Roivant Sciences’s upcoming earnings report date?

Roivant Sciences’s upcoming earnings report date is Feb 16, 2026 which is in 66 days.

How were Roivant Sciences’s earnings last quarter?

Roivant Sciences released its earnings results on Nov 10, 2025. The company reported -$0.202 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.118.

Is Roivant Sciences overvalued?

According to Wall Street analysts Roivant Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences pay dividends?

Roivant Sciences does not currently pay dividends.

What is Roivant Sciences’s EPS estimate?

Roivant Sciences’s EPS estimate is -0.31.

How many shares outstanding does Roivant Sciences have?

Roivant Sciences has 695,491,640 shares outstanding.

What happened to Roivant Sciences’s price movement after its last earnings report?

Roivant Sciences reported an EPS of -$0.202 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 2.667%.

Which hedge fund is a major shareholder of Roivant Sciences?

Currently, no hedge funds are holding shares in ROIV

Roivant Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-14.73%

Trailing 12-Months

Asset Growth

-18.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Roivant Sciences

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences (ROIV) Earnings & Revenues

Historic Earnings Reports

ROIV Company Deck

ROIV Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.View all ROIV earnings summaries

ROIV Stock 12 Month Forecast

Average Price Target

$24.50

▲(21.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","29":"$29","13.25":"$13.25","18.5":"$18.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,13.25,18.5,23.75,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.22,20.818461538461538,21.416923076923077,22.015384615384615,22.613846153846154,23.212307692307693,23.810769230769232,24.409230769230767,25.00769230769231,25.606153846153845,26.204615384615387,26.803076923076922,27.40153846153846,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.22,20.549230769230768,20.878461538461536,21.207692307692305,21.536923076923078,21.866153846153846,22.195384615384615,22.524615384615384,22.853846153846153,23.18307692307692,23.512307692307694,23.841538461538462,24.17076923076923,{"y":24.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.22,20.356923076923074,20.493846153846153,20.63076923076923,20.767692307692307,20.904615384615383,21.04153846153846,21.178461538461537,21.315384615384616,21.45230769230769,21.58923076923077,21.726153846153846,21.863076923076925,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >